Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:2323-2330
Published online before print April 16, 2007, doi: 10.1161/CIRCULATIONAHA.107.691279
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
115/17/2323    most recent
CIRCULATIONAHA.107.691279v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kleinschnitz, C.
Right arrow Articles by Stoll, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kleinschnitz, C.
Right arrow Articles by Stoll, G.
Related Collections
Right arrow Antiplatelets
Right arrow Aggregation
Right arrow Coagulation inhibitors
Right arrow Platelets
Right arrow Animal models of human disease
Right arrow Acute Cerebral Infarction
Right arrow Emergency treatment of Stroke
Right arrowRelated Article

(Circulation. 2007;115:2323-2330.)
© 2007 American Heart Association, Inc.


Stroke

Targeting Platelets in Acute Experimental Stroke

Impact of Glycoprotein Ib, VI, and IIb/IIIa Blockade on Infarct Size, Functional Outcome, and Intracranial Bleeding

Christoph Kleinschnitz, MD*; Miroslava Pozgajova, PhD; Mirko Pham, MD; Martin Bendszus, MD; Bernhard Nieswandt, PhD*; Guido Stoll, MD*

From the Departments of Neurology (C.K., G.S.), Clinical Biochemistry and Pathophysiology (M. Pozgajova, B.N.), and Neuroradiology (M. Pham, M.B.) and the Rudolf Virchow Center, DFG Research Center for Experimental Biomedicine (M. Pozgajova, B.N.), University of Würzburg, Würzburg, Germany.

Correspondence to Guido Stoll, MD, Department of Neurology, Bayerische Julius-Maximilians-Universität Würzburg, Josef-Schneider-Str 11, D-97080 Würzburg, Germany. E-mail stoll_g{at}klinik.uni-wuerzburg.de

Received January 18, 2007; accepted March 9, 2007.

Background— Ischemic stroke is a frequent and serious disease with limited treatment options. Platelets can adhere to hypoxic cerebral endothelial cells by binding of their glycoprotein (GP) Ib receptor to von Willebrand factor. Exposure of subendothelial matrix proteins further facilitates firm attachment of platelets to the vessel wall by binding of collagen to their GPVI receptor. In the present study, we addressed the pathogenic role of GPIb, GPVI, and the aggregation receptor GPIIb/IIIa in experimental stroke in mice.

Methods and Results— Complete blockade of GPIb{alpha} was achieved by intravenous injection of 100 µg Fab fragments of the monoclonal antibody p0p/B to mice undergoing 1 hour of transient middle cerebral artery occlusion. At 24 hours after transient middle cerebral artery occlusion, cerebral infarct volumes were assessed by 2,3,5-triphenyltetrazolium chloride staining. In mice treated with anti-GPIb{alpha} Fab 1 hour before middle cerebral artery occlusion, ischemic lesions were reduced to {approx}40% compared with controls (28.5±12.7 versus 73.9±17.4 mm3, respectively; P<0.001). Application of anti-GPIb{alpha} Fab 1 hour after middle cerebral artery occlusion likewise reduced brain infarct volumes (24.5±7.7 mm3; P<0.001) and improved the neurological status. Similarly, depletion of GPVI significantly diminished the infarct volume but to a lesser extent (49.4±19.1 mm3; P<0.05). Importantly, the disruption of early steps of platelet activation was not accompanied by an increase in bleeding complications as revealed by serial magnetic resonance imaging. In contrast, blockade of the final common pathway of platelet aggregation with anti-GPIIb/IIIa F(ab)2 fragments had no positive effect on stroke size and functional outcome but increased the incidence of intracerebral hemorrhage and mortality after transient middle cerebral artery occlusion in a dose-dependent manner.

Conclusions— Our data indicate that the selective blockade of key signaling pathways of platelet adhesion and aggregation has a different impact on stroke outcome and bleeding complications. Inhibition of early steps of platelet adhesion to the ischemic endothelium and the subendothelial matrix may offer a novel and safe treatment strategy in acute stroke.


 

CLINICAL PERSPECTIVE


Related Article:

Issue Highlights
Circulation 2007 115: 2247. [Full Text]



This article has been cited by other articles:


Home page
BloodHome page
B. Nieswandt
How do platelets prevent bleeding?
Blood, May 15, 2008; 111(10): 4835 - 4835.
[Full Text] [PDF]


Home page
BloodHome page
T. Goerge, B. Ho-Tin-Noe, C. Carbo, C. Benarafa, E. Remold-O'Donnell, B.-Q. Zhao, S. M. Cifuni, and D. D. Wagner
Inflammation induces hemorrhage in thrombocytopenia
Blood, May 15, 2008; 111(10): 4958 - 4964.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
C. Kleinschnitz, S. Braeuninger, M. Pham, M. Austinat, I. Nolte, T. Renne, B. Nieswandt, M. Bendszus, and G. Stoll
Blocking of Platelets or Intrinsic Coagulation Pathway-Driven Thrombosis Does Not Prevent Cerebral Infarctions Induced by Photothrombosis
Stroke, April 1, 2008; 39(4): 1262 - 1268.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. Varga-Szabo, I. Pleines, and B. Nieswandt
Cell Adhesion Mechanisms in Platelets
Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): 403 - 412.
[Abstract] [Full Text] [PDF]